Date | Title | Description | |
---|---|---|---|
25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
21 Feb 2023 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
21 Feb 2023 | On business and financial situation | The company releases the Integrated Report for the year 2022 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
05 Nov 2020 | On business and financial situation | The company releases the press release related to the 2020 first nine months financial results | Download |
20 Oct 2020 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
15 Oct 2020 | Announcement of general shareholders’ meeting | In view of the exceptional circumstances derived from the spread of Covid-19, the Company has agreed that the Ordinary General Meeting be held by exclusively telematic means. | Download |
01 Oct 2020 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the third quarter of 2020 | Download |
11 Sep 2020 | Announcement of general shareholders’ meeting | Rovi releases the information related to its 2020 General Shareholders Meeting. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Oct 2018 | Share capital increases and reductions | Information on the registration in the Commercial Registry of Madrid of the notarial deed regarding the capital increase | Download |
05 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | Information about the possibility that Jefferies International Limited carries out stabilisation transactions within the framework of the capital increase excluding pre-emptive subscription rights of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A. | Download |
04 Oct 2018 | Share capital increases and reductions | Directors’ Report and Independent Expert Report related to capital increase excluding preferential subscription rights | Download |
04 Oct 2018 | Liquidity contracts and specialists | The Company informs that has temporarily suspended liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U. | Download |
04 Oct 2018 | Share capital increases and reductions | Information on price fixing and outcome of the private placement related to capital increase addressed to institutional investors, excluding preferential subscription rights | Download |